Clinical evaluation of a novel enhanced depth-of-focus intraocular lens (EDOF IOL) with a low add trifocal, diffractive pattern and correction of chromatic aberration

Session Details

Session Title: Refractive
Session Date/Time: Friday 09/02/2018 | 10:30-12:00
Paper Time: 10:36
Venue: Annex A

First Author: C.Lindel GERMANY
Co Author(s): F. Kretz  D. Breyer  H. Kaymak  A. Abdassalam  M. Muller  G. Auffarth and M. Gerl  

Abstract Details

Purpose:

A prospective study to evaluate the refractive & functional results, patient satisfaction and defocus curve after binocular implantation of an enhanced depth of focus intraocular lens (EDOF IOL).

Setting:

Augenärzte Gerl, Kretz & Kollegen, Augenklinik Ahaus & Augentagesklinik Rheine, Ahaus, Germany

Methods:

In a prospective ongoing study 20 eyes of 10 cataract patients received binocular EDOF IOL (AT LARA 829, Carl Zeiss Meditech, Germany). Both eyes were targeted closest to emmetropia. Pre- and postoperative, monocular and binocular functional results (CDVA, UDVA, DCIVA [90cm, 80cm, 60cm], DCNVA [40cm], Defocus curve; [logMAR]) refractive outcome, Halo and Glare Simulator and patient satisfaction score were evaluated.

Results:

Median postoperative spherical equivalent was -0.06 D (1.56). Mean postoperative monocular UDVA, CDVA and DCNVA were 0.02 (0.10), 0.00 (0.06) and 0.30 (0.19), respectively with binocular values of -0.05 (0.09), -0.10 (0.06) and 0.25 (0.14). Monocular DCIVA in 90cm, 80cm and 60cm was 0.05 (0.12), 0.10 (0.11) and 0.12 (0.15), respectively with binocular values of -0.10 (0.15), 0.05 (0.13) and 0.02 (0.15). Defocus curve analysis show a stable visual acuity from +0.5 to -1.5 D.

Conclusions:

Binocular implantation of an EDOF IOL with a new diffractive pattern with the correction of chromatic aberration show a good refractive predictability. Functional results especially from to distance to near show excellent results with a slight increase comparing monocular to binocular visual function. Still binocular DCNVA in 40cm shows a acceptable results offering a high degree of patient satisfaction.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, , travel has been funded, fully or partially, by a competing company, , travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, , research is funded, fully or partially, by a competing company, , research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, , receives nonNonemonetary benefits from a competing company., , receives nonNonemonetary benefits from a company producing, developing or supplying the product or procedure presented., , receives consulting fees, retainer, or contract payments from a competing company